Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,874 | -21,630 | -13,094 | -7,915 | -4,311 |
| Depreciation Amortization | 879 | 3,364 | 2,649 | 1,594 | 468 |
| Income taxes - deferred | N/A | -86 | N/A | N/A | N/A |
| Accounts receivable | -780 | 1,217 | 962 | 1,028 | 848 |
| Accounts payable and accrued liabilities | 296 | -992 | -1,260 | -958 | -865 |
| Other Working Capital | -115 | -46 | -431 | -828 | -58 |
| Other Operating Activity | 2,633 | 9,623 | 4,386 | 1,267 | 673 |
| Operating Cash Flow | $-1,961 | $-8,550 | $-6,788 | $-5,812 | $-3,245 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -119 | -2,390 | -230 | -82 | N/A |
| Investing Cash Flow | $-119 | $-2,390 | $-230 | $-82 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,000 | 9,500 | 4,500 | N/A | 2,500 |
| Debt Issued | N/A | 955 | 955 | 955 | N/A |
| Common Stock Issued | N/A | 679 | 610 | 3,610 | N/A |
| Other Financing Activity | 0 | -59 | -59 | -59 | -25 |
| Financing Cash Flow | $1,000 | $11,075 | $6,006 | $4,506 | $2,475 |
| Exchange Rate Effect | 19 | -113 | -66 | -21 | -48 |
| Beginning Cash Position | 3,007 | 2,985 | 2,985 | 2,985 | 2,985 |
| End Cash Position | 1,946 | 3,007 | 1,907 | 1,576 | 2,167 |
| Net Cash Flow | $-1,061 | $22 | $-1,078 | $-1,409 | $-818 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,961 | -8,550 | -6,788 | -5,812 | -3,245 |
| Capital Expenditure | -119 | -2,390 | -230 | -82 | N/A |
| Free Cash Flow | -2,080 | -10,940 | -7,018 | -5,894 | -3,245 |